Histone demethylating agents as potential S-adenosyl-l-methionine-competitors

R. Navakauskiene, M. Mori, M. S. Christodoulou, A. Zentelyte, B. Botta, L. Dalla Via, F. Ricci, G. Damia, D. Passarella, C. Zilio, N. Martinet

Research output: Contribution to journalArticlepeer-review


Histone H3 methylation on K9 and/or K27 depends on histone lysine methyltransferases (KMTs). EZH2, one of the components of the PRC2 complex, catalyzes the trimethylation of histone H3K27, which is associated with transcriptional repression and tumor development. H3K9me3 mediated gene silencing may result from other KDMs such as G9a/GLP, SUV39H1-2, SETDB1, CCLD8 and RIZ1. Their disturbance leads to defective cell mitosis. It is therefore desirable to find small molecules that are able to decrease H3K9 and K27 tagging to reinitiate gene transcription. Most KDM inhibitors are still based on SAM co-factor competition/modulation. Herein, functional screening of a diversity library proved to be a useful tool for finding new specific KDM inhibitors; the use of SAM-based pharmacophoric models facilitated the understanding of their possible mechanism of action.

Original languageEnglish
Pages (from-to)1245-1255
Number of pages11
Issue number6
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Biochemistry
  • Pharmaceutical Science


Dive into the research topics of 'Histone demethylating agents as potential S-adenosyl-l-methionine-competitors'. Together they form a unique fingerprint.

Cite this